Trending...
- $1B Target by 2027 Amid eSIM, Global Roaming Expansion; $57.6M Q1 Revenue and Market Uplisting, Advancing Toward IQSTEL, Inc. (Stock Symbol: IQST)
- Marc Soucy's Newest Music Series Approaches Its One Year Mark
- LIB TH-50/TH-80 Benchtop Environmental Chamber Drives Global Demand
FAYETTEVILLE, Ark. - Arizonar -- Lineus Medical has been granted five additional international patents for its flagship product, SafeBreak® Vascular, in Korea, Brazil, Australia, India, and China. These patents strengthen Lineus Medical's intellectual property portfolio as the company continues expanding into major healthcare markets worldwide. They also mark a key milestone toward obtaining regulatory clearances and establishing distribution partnerships in these regions.
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on The Arizonar
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on The Arizonar
- Solomon Eye Appoints Dr. Nancy Draskovic as Clinical Director of Ocular Surface Disease
- 150% Increase in Fiscal Q2 Sales vs Previous Year to $750,000; Continuous Record Quarters & Profitability for Homebuilding Product: Innovative Designs
- Use Dogecoin (DOGE) to mine Bitcoin (BTC) and earn passive income at home
- European Tech Startup RoarFun discovers a gap in the U.S. market with a branded racing simulator rental at Atlanta's MRO Americas Aviation Convention
- Degrees of Justice: Attorney Frank Walker Charts the Future of Criminal Justice with Ph.D Degree
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
Source: Lineus Medical
Filed Under: Health, Technology
0 Comments
Latest on The Arizonar
- Perspectives: Jellyfish Publication of an exciting new human clinical trial of proprietary KollaJell™ collagen peptide formulation
- Governor Katie Hobbs Announces Members of Arizona's First AI Steering Committee
- Mesa: Electric Aircraft Demonstration at Falcon Field Airport Marks New Era in Aviation
- Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement
- CEO Selected to Present at Wall Street Conference on May 21, 2025 for Suicidal Depression / PTSD: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
- $10 Million Plan to Acquire Successful Remote Lottery Platform: Expanding Global Footprint into Live Entertainment: Lottery.com (Stock Symbol: LTRY)
- Assent Launches Carbon Border Adjustment Mechanism Solution to Help Manufacturers Meet Regulatory Requirements
- Q1 2025 Revenue Soars 92% to $1.13M on Strategic Acquisitions, Organic Growth & Breakthroughs in AI Drones & Quantum Tech: ZenaTech Stock Symbol: ZENA
- Savista Retreat Announces Monthly Yoga, Wellness & Experiential Retreats in Jaipur
- Robert Tsigler Selected by NADC as Top 1% Attorney in the U.S. for 2025
- Arizona's Family Chiropractic: Redefining Chiropractic Care in Gilbert, AZ
- **Award-Winning Dystopian Book Series Hitting Too Close to Home**
- Unified Restoration LLC Launches in Mesa to Offer 24/7 Water, Mold, Fire & Asbestos Damage Services
- Neoware Unveils Strategic Transformation as a Specialist "Data to Intelligence" Partner
- Phoenix Implant Clinic Introduces Upfront Cost Page to Strengthen Patient Trust
- Pregis Expands its Curbside-Recyclable Paper Packaging Portfolio with White EasyPack GeoTerra
- Advanced Dental Techniques Recognized as a Top Family Dentist for 2024
- Save 10 Percent on KeysCaribbean Vacation Home Rentals' Nightly Rate with 'Spring into Summer Sale'
- Solomon Eye Physicians & Surgeons announces appointment of Ann Reiling as Chief Operations Officer
- Flat-Rate Pharmacy Marketing Solution to Combat Industry Crisis